Clinical Use of Cold and Contact Heat-evoked Potentials: Normative Values

NCT ID: NCT05699317

Last Updated: 2023-03-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-20

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective interventional study aims at recording contact heat evoked potentials (CHEPs) and cold evoked potentials (CEPs) in a healthy population sample in an aim to derive normative values which could be used to evaluate evoked potentials (EPs) of patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Population sample of 80 healthy volunteers between 26 and 75 years old will be recruited and will be categorized into 5 age subgroups (26-35, 36-45, 46-55, 56-65, 66-75 years old).

Upon arrival, participants will be reminded of the aims and of the content of the experiment. After informed consent (recorded in writing), healthy subjects will be screened with a baseline examination:

1. brief neurological examination
2. sensory nerve conduction study-related
3. quantitative sensory testing

If the baseline examination screening is considered normal, CEPs and CHEPs will be performed. To avoid bias, the side and order of the tests will be randomized.

All thermal stimuli for CEPs and CHEPs will be delivered delivered using a contact thermal stimulator (TCS model II.1, QST.Lab, Strasbourg, France).

Only stimuli that are safe and acceptable for the subject will be used in the study, and all experimental procedures can be interrupted at any time by the participant, with no detrimental effect.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Establishing Normative Values of Cold and Contact Heat-evoked Potentials

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Group Type EXPERIMENTAL

Thermal stimuli

Intervention Type OTHER

Thermal stimuli will be delivered delivered using a contact thermal stimulator (TCS model II.1, QST.Lab, Strasbourg, France).

Target temperatures will be set to reach 10°C (CEP) and 60°C (CHEP) at a rate of 300°C/s.

Stimulus duration will be set 200 ms. The stimulator will be manually held against the skin by the experimenter and slightly displaced within the first 10 cm of the distal extremity of the volar forearm being investigated, marked on the skin of the participant, after each stimulus. A total of 30 stimuli per temperature and testing site will be applied.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Thermal stimuli

Thermal stimuli will be delivered delivered using a contact thermal stimulator (TCS model II.1, QST.Lab, Strasbourg, France).

Target temperatures will be set to reach 10°C (CEP) and 60°C (CHEP) at a rate of 300°C/s.

Stimulus duration will be set 200 ms. The stimulator will be manually held against the skin by the experimenter and slightly displaced within the first 10 cm of the distal extremity of the volar forearm being investigated, marked on the skin of the participant, after each stimulus. A total of 30 stimuli per temperature and testing site will be applied.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy volunteers between 26 and 75 years old having a normal baseline testing.

Exclusion Criteria

* Age\<26 and \>75 years old
* Known neurological condition.
* Acute or chronic pain condition.
* Currently taking drugs that may influence the recording of evoked potentials (analgesics, psychotropic substances, antiepileptics…).
* History of neurological, or metabolic disorder.
* Inability to complete study task.
* History of chemotherapy.
* Habitual substance abuse(alcoholic beverages intake \>21 units/week for males, \>14 units/week for females.)
* Being a volley ball player (due to risk of modified sensibility of the volar forearm skin)
* Abnormal baseline neurological, SNC or QST testing
Minimum Eligible Age

26 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Université Catholique de Louvain

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

André Mouraux, Prof

Role: PRINCIPAL_INVESTIGATOR

UCLouvain, IONS

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institute of Neuroscience

Brussels, Woluwe Saint Lambert, Belgium

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yoshnee Foolchand, MD

Role: CONTACT

+32483438840

André Mouraux, Pr

Role: CONTACT

+32 2 764 73 86

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

André MOURAUX, Pr

Role: primary

+32 2 764 73 86

Yoshnee FOOLCHAND, Dr

Role: backup

+32483438840

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PET ET PSYCHOMOT

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.